Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.40)
# 327
Out of 5,148 analysts
84
Total ratings
57.89%
Success rate
18.19%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Hold | $190 → $193 | $188.05 | +2.63% | 6 | Feb 9, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $61.43 | +49.76% | 5 | Feb 3, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $88 → $110 | $94.24 | +16.72% | 4 | Jan 5, 2026 | |
| SEPN Septerna | Initiates: Buy | $34 | $28.64 | +18.72% | 1 | Dec 15, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $116 | $90.10 | +28.75% | 6 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $35 → $56 | $42.03 | +33.24% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $580 → $640 | $435.62 | +46.92% | 2 | Nov 19, 2025 | |
| INCY Incyte | Reiterates: Hold | $79 → $93 | $100.04 | -7.04% | 12 | Oct 29, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $54 → $44 | $43.48 | +1.20% | 5 | Oct 20, 2025 | |
| VTRS Viatris | Initiates: Buy | $15 | $15.70 | -4.46% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $32.97 | +51.65% | 1 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $790.81 | +2.68% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $13.39 | -17.85% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $13.91 | +79.73% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,017.97 | +1.97% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $234.26 | -7.37% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $27.26 | +17.39% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $29.70 | +68.35% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.37 | +3,841.61% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.82 | +157.73% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $15.81 | +127.70% | 1 | Jul 31, 2024 |
Biogen
Feb 9, 2026
Maintains: Hold
Price Target: $190 → $193
Current: $188.05
Upside: +2.63%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $61.43
Upside: +49.76%
Protagonist Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $88 → $110
Current: $94.24
Upside: +16.72%
Septerna
Dec 15, 2025
Initiates: Buy
Price Target: $34
Current: $28.64
Upside: +18.72%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $90.10
Upside: +28.75%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $35 → $56
Current: $42.03
Upside: +33.24%
Madrigal Pharmaceuticals
Nov 19, 2025
Maintains: Buy
Price Target: $580 → $640
Current: $435.62
Upside: +46.92%
Incyte
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $100.04
Upside: -7.04%
Scholar Rock Holding
Oct 20, 2025
Maintains: Buy
Price Target: $54 → $44
Current: $43.48
Upside: +1.20%
Viatris
Oct 15, 2025
Initiates: Buy
Price Target: $15
Current: $15.70
Upside: -4.46%
Oct 15, 2025
Initiates: Buy
Price Target: $50
Current: $32.97
Upside: +51.65%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $790.81
Upside: +2.68%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $13.39
Upside: -17.85%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $13.91
Upside: +79.73%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,017.97
Upside: +1.97%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $234.26
Upside: -7.37%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $27.26
Upside: +17.39%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $29.70
Upside: +68.35%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.37
Upside: +3,841.61%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.82
Upside: +157.73%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $15.81
Upside: +127.70%